TransMedics Group (NASDAQ:TMDX) Shares Gap Up After Better-Than-Expected Earnings

Shares of TransMedics Group, Inc. (NASDAQ:TMDX) gapped up before the market opened on Friday following a stronger than expected earnings report. The stock had previously closed at $68.98, but opened at $79.12. TransMedics Group shares last traded at $83.8150, with a volume of 465,606 shares changing hands.

The company reported $0.51 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.30 by $0.21. TransMedics Group had a net margin of 22.69% and a return on equity of 15.88%. The company had revenue of $203.01 million for the quarter, compared to analyst estimates of $178.06 million. During the same quarter last year, the firm posted $0.66 earnings per share. The business’s quarterly revenue was up 41.1% on a year-over-year basis.

Key Stories Impacting TransMedics Group

Here are the key news stories impacting TransMedics Group this week:

• Positive Sentiment: Third-quarter revenue reached $203 million, up 41.1% year over year and above analyst expectations of about $178 million. EPS of $0.51 also beat the roughly $0.30 consensus. TransMedics Reports Third Quarter 2026 Financial Results
• Positive Sentiment: TransMedics raised its 2026 revenue guidance to $764 million–$774 million, signaling confidence in continued revenue growth. TransMedics raises 2026 revenue guidance
• Negative Sentiment: The company’s ENHANCE Part B and DENOVO catalysts have shifted to early 2027, delaying potential near-term milestones. EPS also declined from $0.66 in the year-ago quarter despite beating the latest consensus. TransMedics raises 2026 revenue guidance

Wall Street Analysts Forecast Growth

A number of brokerages have commented on TMDX. Zacks Research upgraded shares of TransMedics Group from a “strong sell” rating to a “hold” rating in a report on Monday. TD Cowen restated a “buy” rating and set a $120.00 target price on shares of TransMedics Group in a research note on Tuesday, September 8th. Weiss Ratings upgraded TransMedics Group from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, August 31st. Barclays started coverage on TransMedics Group in a research report on Wednesday, October 7th. They set an “overweight” rating and a $120.00 target price on the stock. Finally, UBS Group cut their price target on TransMedics Group from $80.00 to $77.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 5th. Five research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $118.20.

Insider Buying and Selling at TransMedics Group

In related news, Director David Weill bought 1,336 shares of the business’s stock in a transaction dated Friday, September 11th. The shares were acquired at an average price of $81.63 per share, for a total transaction of $109,057.68. Following the purchase, the director owned 16,392 shares in the company, valued at $1,338,078.96. This trade represents a 8.87% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 6.90% of the company’s stock.

Institutional Trading of TransMedics Group

Hedge funds and other institutional investors have recently bought and sold shares of the company. Pinnacle Wealth Planning Services Inc. increased its stake in TransMedics Group by 24.9% during the third quarter. Pinnacle Wealth Planning Services Inc. now owns 874 shares of the company’s stock valued at $73,000 after purchasing an additional 174 shares during the last quarter. Plan A Wealth LLC lifted its position in shares of TransMedics Group by 3.9% in the 3rd quarter. Plan A Wealth LLC now owns 5,370 shares of the company’s stock worth $448,000 after buying an additional 203 shares during the last quarter. Whittier Trust Co. of Nevada Inc. boosted its holdings in shares of TransMedics Group by 95.0% in the 1st quarter. Whittier Trust Co. of Nevada Inc. now owns 425 shares of the company’s stock valued at $45,000 after buying an additional 207 shares during the period. IFP Advisors Inc boosted its holdings in shares of TransMedics Group by 4.8% in the 2nd quarter. IFP Advisors Inc now owns 4,652 shares of the company’s stock valued at $309,000 after buying an additional 213 shares during the period. Finally, HB Wealth Management LLC boosted its holdings in shares of TransMedics Group by 1.5% in the 2nd quarter. HB Wealth Management LLC now owns 15,062 shares of the company’s stock valued at $1,000,000 after buying an additional 219 shares during the period. 99.67% of the stock is owned by institutional investors.

TransMedics Group Trading Up 21.1%

The company has a current ratio of 6.62, a quick ratio of 6.07 and a debt-to-equity ratio of 1.62. The business’s 50-day moving average is $79.68 and its two-hundred day moving average is $93.44. The firm has a market cap of $2.89 billion, a P/E ratio of 21.47, a P/E/G ratio of 1.00 and a beta of 2.14.

About TransMedics Group

TransMedics Group, Inc is a medical technology company focused on improving organ transplantation through systems that preserve and assess donor organs outside the body. The company’s primary platform is the Organ Care System (OCS), a portable, technology-enabled perfusion system designed to maintain organs in a functioning, near-physiologic state during transport and evaluation.

TransMedics offers OCS products for heart, lung and liver transplantation. Its systems are intended to support the use of organs that may not otherwise be suitable for conventional cold-storage methods, potentially expanding the donor pool and providing transplant teams with additional information when evaluating organs for transplantation.

Founded in 1998 and headquartered in Andover, Massachusetts, TransMedics serves transplant centers in the United States and select international markets.